

**Issue Date: July 1, 2014**

**Call for Grant Notification:** Genentech Medical Education & Research Grants – *Research Projects (Stroke)*

Genentech, a member of the Roche Group, is actively seeking applications for financial support of Research Projects subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds for clinical fellowships.

**Purpose:** As part of our scientific mission, Genentech provides grants for scientific projects and fellowship programs that are aligned with our mission to (1) foster advances in scientific research and discovery; and (2) support advanced study by clinical and research professionals at accredited universities or training institutions.

Genentech CGNs are posted on the Genentech website (<http://funding.gene.com>) along with the website for the Society for Academic Continuing Medical Education (SACME). In addition, an email is sent out to all registered users of the Genentech Financial Request System (gFRS).

**Eligibility Criteria:** Applicant must be registered on the Genentech Financial Request System (gFRS).

Scientific Project support provides funding for general research, translational research, other research and development projects, and/or other initiatives of research organizations, labs and academic institutions. Research collaborations, clinical trials and associated correlative research involving or undertaken relating to Genentech or Roche products (whether investigational and/or approved for other indications ) are excluded from Scientific Project support.

**Submission Instructions:** Submit applications online through gFRS, which can be accessed via <http://funding.gene.com>. When submitting the application, please ensure the following are completed:

1. Select the Therapeutic Area, and the Disease State for the grant(s) that you are submitting.
2. Include “**CGN Stroke SEPT\_2014\_[Insert Title]**” in the Program Title of the grant application
3. Complete ALL sections of the online grant request form
4. Upload all documentation as requested by the system.

**Deadline for Submission of Application(s): September 2, 2014 (11:59 PM Pacific Time)**

Please note: Requests must be submitted at least 60 days prior to the project/program start date.

**Award Decision Date/Mechanism:** Approvals and denials will be communicated via standard grant-submission means (email notifications) no later than **September 27, 2014**. *There have been no pre-determined approvals, nor any identified preferred providers. All submissions will be reviewed equally and thoroughly.* Applicants should not respond to this CGN unless they have read and understand the terms, purpose, identified gap, research scope and request identified below.

### Terms

Scope	Funding Available	Grant Type	Gap	Description
Improving quality of care for stroke and/or mild and rapidly improving stroke patients	1 research project (approximately \$150,000)	Research project	Stroke is the leading cause of serious long-term disability in the United States (1). Nevertheless significant disparities exist in how communities are affected by stroke. Several research studies have identified that stroke mortality varies by age, sex, race, socioeconomic status and ethnicity (2-5). Underrepresented populations in urban areas are known to be particularly at risk and remain a significant hurdle to achieve equality in stroke care (5-6).	Genentech is seeking support for 1 research project with the focus of increasing quality of care for patients at risk of stroke in a community where this disease carries a heavy burden. The successful research project will use established technology to identify patients at risk for stroke and/or mild and rapidly improving stroke and engage both the patients and health care providers in a personalized care plan. Proposals are encouraged to include methods for capturing data concerning quantifiable improvements in quality of care, care coordination, stroke incidence and other patient centric variables. Finally, innovative, low cost strategies to identify gaps in care are highly encouraged.
Novel applications for modern communication technology in telestroke programs geared for rural environments	1 research project (approximately \$150,000)	Research Project	In the United States, nearly 800,000 people experience a stroke each year. Stroke is now the leading cause of chronic disability in the general population (1). Several clinical studies have determined that successful stroke treatment is extremely time-dependent (7-9). Nevertheless, in many rural areas with limited access to healthcare, the time required to accurately diagnose stroke in a patient presenting with focal neurological deficits is significantly increased due to the distance between the patient's location and the healthcare facility.	Genentech is seeking to support 1 research project that uses established wireless communication technology to meet the clinical care needs of stroke patients in communities that don't have an active telestroke network in place. The successful research project should use easily transferable technology and innovative solutions to address cost, clinician education, and other recognized barriers to telestroke adoption (9). In addition, research projects should be designed to capture quantifiable data regarding both the effectiveness and gaps address by the telestroke program.

***\*Genentech is also committed to providing non-solicited grant support in all disease areas.***

### **Genentech's Grant Decision-Making Criteria**

Please refer to the publicly available criteria, which can be found at <http://funding.gene.com>.

### **Terms and Conditions**

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines.
2. This CGN does not commit Genentech to award a grant or to pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reason, and in fairness to all providers, all communications about this CGN must come exclusively to Genentech's department for Medical Education & Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow instruction within this CGN may result in a denial.

### **Transparency**

Genentech, at its sole discretion, has the right to disclose the details of funded independent medical education activities, including those that may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount. The information may be disclosed to the public in a manner including, but not limited to, disclosure on the Genentech website.

### **References**

1. Pearce, J.M. Pituitary tumours and acromegaly (Pierre Marie's disease). *Journal of Neurology, Neurosurgery, and Psychiatry*, 2002;73, 394.
2. Nabarro, J.D. Acromegaly. *Clinical Endocrinology*, 1987;26:481– 512.
3. Molitch, M.E. Clinical manifestations of acromegaly. *Endocrinology and Metabolism Clinics of North America*, 1992;21:597–614.
4. Beauregard, C., Truong, U., Hardy, J. et al. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. *Clinical Endocrinology*, 2003;58:86–91.
5. Mestron, A., Webb, S.M., Astorga, R. et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). *European Journal of Endocrinology*, 2004;151:439–446.
6. Swearingen, B., Barker, F.G. II, Katznelson, L. et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. *Journal of Clinical Endocrinology and Metabolism*, 1998;83:3419–3426.

7. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM & Freda PU. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under recognized and under-diagnosed. *Clinical Endocrinology*, 2010 72: 203–208.
8. Schneider HJ, Kosilek RP, Gunther M, Roemmler J, Stalla GK, Sievers C, Reincke M, Schopohl J, Wurtz RP. A Novel approach to the detection of acromegaly: Accuracy of diagnosis by automatic face classification *J. clin Endocrinol. Metab.* 2011-0237, in press
9. Kleinfeld NR. Diabetes and its awful toll quietly emerge as a crisis. New York Times. January, 9 2006;1
10. Sullivan J. As diabetes rises, doctors numbers fall. Philadelphia Inquirer. September 13, 2006;A1.
11. Toledo FG, Stewart AF, The Academic and Clinical Endocrinology Physician workforce in the US. *J. clin Endocrinol. Metab*, 2011, 96:4:942-944
12. K. S. Alatzoglou & M. T. Dattani Genetic causes and treatment of isolated growth hormone deficiency—an update *Nat Rev Endocrinol* 2010,6:562-576
13. Weedon, M.N., Lango, H., Lindgren, C.M., Wallace, C., Evans, D.M., Mangino, M., Freathy, R.M., Perry, J.R., Stevens, S., et al. (2008). Genome-wide association analysis identifies 20 loci that influence adult height. *Nat Genet* 40, 575-583.